Werewolf Therapeutics

HOWL · NASDAQ

$1.05+$0.01 (+0.96%)TodayMarket closed · Oct 20, 7:51 PM ET

Prev close $1.04

Latest news

Press releaseSep 9, 2:49 PM ETPRNewswire
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?
Press releaseSep 4, 11:21 AM ETPRNewswire
Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders?
Press releaseAug 23, 3:40 PM ETBusiness Wire
HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Press releaseAug 23, 2:00 PM ETPRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC
NewsAug 21, 1:06 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsAug 21, 12:01 PM ETAvi Kapoor
Gold Moves Higher; US Composite PMI Surges In August
NewsAug 21, 10:02 AM ETAvi Kapoor
Dow Jumps 350 Points; BJ's Wholesale Club Posts Upbeat Earnings
NewsAug 21, 9:33 AM ETVandana Singh
Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal
NewsAug 21, 9:30 AM ETSurbhi Jain
One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story
NewsAug 21, 8:06 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseAug 21, 8:00 AM ETGlobe Newswire
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
Press releaseAug 21, 8:00 AM ETGlobe Newswire
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
NewsAug 21, 12:34 AM ETMohd Haider
Werewolf Therapeutics (HOWL) Stock Is Trending Overnight—Here's Why It Jumped 90% After Hours
NewsAug 20, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsAug 10, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsJul 31, 7:27 AM ET
Werewolf Therapeutics Q2 EPS $0.08 Beats $(0.29) Estimate, Sales $21.000M
Press releaseJul 31, 7:00 AM ETGlobe Newswire
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
NewsJul 24, 1:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
Press releaseMay 7, 4:05 PM ETGlobe Newswire
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
NewsApr 28, 1:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsApr 23, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsMar 27, 7:11 AM ET
Earnings Scheduled For March 27, 2026
Press releaseMar 27, 7:00 AM ETGlobe Newswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Press releaseDec 18, 8:00 AM ETGlobe Newswire
Werewolf Therapeutics Announces Pipeline and Business Updates
NewsNov 5, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseNov 4, 7:00 AM ETGlobe Newswire
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Press releaseOct 8, 8:00 AM ETGlobe Newswire
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Press releaseSep 2, 8:00 AM ETGlobe Newswire
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Press releaseAug 14, 7:00 AM ETGlobe Newswire
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Press releaseMay 29, 8:00 AM ETGlobe Newswire
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
Press releaseMay 5, 8:05 AM ETGlobe Newswire
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Press releaseMay 5, 8:00 AM ETGlobe Newswire
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
Press releaseMar 31, 8:00 AM ETGlobe Newswire
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Press releaseMar 4, 8:00 AM ETGlobe Newswire
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
Press releaseNov 20, 8:00 AM ETGlobe Newswire
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Press releaseSep 3, 8:00 AM ETGlobe Newswire
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?

Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders?

HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC

12 Health Care Stocks Moving In Friday's Intraday Session

Gold Moves Higher; US Composite PMI Surges In August

Dow Jumps 350 Points; BJ's Wholesale Club Posts Upbeat Earnings

Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal

One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story

12 Health Care Stocks Moving In Friday's Pre-Market Session

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

Werewolf Therapeutics (HOWL) Stock Is Trending Overnight—Here's Why It Jumped 90% After Hours

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Werewolf Therapeutics Q2 EPS $0.08 Beats $(0.29) Estimate, Sales $21.000M

Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

12 Health Care Stocks Moving In Friday's Intraday Session

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Thursday's After-Market Session

Earnings Scheduled For March 27, 2026

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Announces Pipeline and Business Updates

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference